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Abstract
A polymorphism on the MUC5B promoter (rs35705950) has been associated with idiopathic pulmonary fibrosis (IPF) but not
with systemic sclerosis (SSc) with interstitial lung disease (ILD). We genotyped the MUC5B promoter in the first 142 patients
of the French national prospective cohort of IPF, in 981 French patients with SSc (346 ILD), 598 Italian patients with SSc (207
ILD), 1383 French controls and 494 Italian controls. A meta-analysis was performed including all American data available.
The T risk allele was present in 41.9% of the IPF patients, 10.8% of the controls (P = 2610–44), OR 6.3 [4.6–8.7] for
heterozygous patients and OR 21.7 [10.4–45.3] for homozygous patients. Prevalence of the T allele was not modified
according to age, gender, smoking in IPF patients. However, none of the black patients with IPF presented the T allele. The
prevalence of the T risk allele was similar between French (10%) and Italian (12%) cohorts of SSc whatever the presence of
an ILD (11.1% and 13.5%, respectively). Meta-analysis confirmed the similarity between French, Italian and American cohorts
of IPF or SSc-ILD. This study confirms 1) an association between the T allele risk and IPF, 2) an absence of association with
SSc-ILD, suggesting different pathophysiology.
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Introduction
Lung fibrosis is a common trait of idiopathic pulmonary fibrosis
(IPF) and systemic sclerosis (SSc) with interstitial lung disease
(ILD). Indeed, ILD is present in almost 40% of the patient with
SSc and is the major cause of death during SSc [1]. However the
most common histological and radiological pattern observed in
SSc-ILD is non specific interstitial pneumonia (NSIP), whereas the
pattern associated with IPF is usual interstitial pneumonia (UIP)
[2]. There is still a debate concerning the pathophysiology of NSIP
and UIP, there is evidence that both patterns share aetiologies and
can occur in the same context.
Both IPF and SSc are considered as genetic complex diseases,
and occur in genetically predisposed individuals who have
experienced certain environmental or stochastic stimuli [3]. An
association between a functional polymorphism located in the
putative promoter region of the MUC5B gene (rs35705950) and
sporadic and familial IPF has been recently identified in 3
American cohorts including 916 patients [4,5] and was recently
confirmed in 2 genome wide association studies [6,7]. A candidate
gene association study which investigated MUC5B rs35705950 in
109 individuals having SSc-ILD suggested a lack of association [8].
Moreover a recent gene association study in England confirmed
an association with IPF (n= 110) and a lack of association with
SSc-ILD (n = 440) or sarcoidosis (n = 180) [9]. To date, no
information is available regarding the association betweenMUC5B
rs35705950 and IPF or SSc-ILD in French or Italian populations.
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These findings prompted us to test an association between the
MUC5B rs35705950 variant and i) IPF in the French population,
and ii) SSc-related ILD in two large European Caucasian
populations. We then performed a meta-analysis of the American
and European data in IPF and SSc.
Methods
Study populations
IPF populations. A French prospective and multicentric
cohort of recently diagnosed IPF (the COFI cohort) was
established starting in 2008. Inclusion criteria comprised a
diagnosis of IPF based upon either surgical biopsy or a
characteristic CT scan pattern according to the 2001 ATS/ERS
consensus [10]. The first imaging allowing the diagnosis of IPF
had to date back to a maximum of 9 months prior to inclusion. All
demographic, comorbidity, clinical and functional data were
prospectively and serially recorded.
SSc populations and controls. We studied two European
cohorts of patients with SSc and their associated controls. The
French cohort included 981 SSc patients and 1229 controls
coming from the French network as previously described [11].
The replication step came from Italy included 598 SSc patients
and 494 controls [11]. Of note all SSc patients and controls were
Caucasian. Patients were classified according to LeRoy’s cutane-
ous subtypes [12]. SSc patients were tested for antinuclear
antibodies (ANA) using indirect immunofluorescence (IIF) and
HEp-2 cells as antigen substrate (Antibodies Inc., Davis, CA).
Specific SSc antibodies were systematically assessed; anti-centro-
mere antibodies (ACAs) were determined by their distinctive IIF
pattern on HEp-2 cells. Anti-topoisomerase I antibodies (TOPO)
were determined by counter immuno-electrophoresis.
ILD was defined as the presence of ground glass opacity and/or
reticular opacities in a peripheral distribution on chest CT scan,
however a classification according to the UIP or NSIP pattern was
not performed. CT scan was not available for 99 and 7 patients of
the French and Italian cohorts respectively.
Local institutional review board approval was obtained for
every study subject and written informed consent was obtained
from all subjects (Ethical Committee of Firenze, Comite´ pour la
Protection des Personnes Ile de France X, Aulnay sous Bois).
Genotyping
All the subjects were genotyped for the MUC5B rs35705950
SNP using a competitive allele specific PCR system (Kaspar
genotyping, Kbioscience, Hoddeston, UK) and Taqman SNP
genotyping assay-allelic discrimination method (Applied Biosys-
tem, Foster City, CA) as previously described [11]. The average
genotype completeness was 99% for SSc and IPF and controls
samples for the SNP investigated. The accuracy was .99%,
according to duplicate genotyping of 10% of all samples.
Statistical analysis
The statistical analyses were performed using the R computer
package software (version 2.10.1). The level of significance for all
the tests corresponds to a type-I error-rate a=5%. Tests for
conformity to Hardy–Weinberg equilibrium (HWE) were per-
formed using a standard x 2 test (1 degree of freedom) to test for
differences between observed and expected genotype distributions
based on control population allele frequencies.
Individual association analyses of the MUC5B rs35705950 SNP
with IPF or SSc were performed by comparing cases and controls
with a Fisher’s exact or Chi2 test on genotypes. Blacks individuals
with IPF were excluded from analysis as our controls were all
Caucasians. The corresponding ORs were assessed using a
standard logistic regression analysis with the most frequent
homozygous genotype in the control population taken as the
reference. The same procedure was applied in subgroups stratified
according to SSc phenotypes, compared to controls.
Meta-analysis of rs35705950
We performed a systematic review and the meta-analysis of all
data published up to December 2012. We searched Medline via
PubMed with the terms ‘‘MUC5B’’ for articles published in
English that provided 3 relevant articles. We did not find other
articles with hand-searched reference lists of clinically relevant
articles. We contacted the corresponding author that provided us
the full data. We therefore fulfilled the PRISMA guidelines.
Idiopathic pulmonary fibrosis. The meta-analysis included
the data obtained in the French IPF population from this study,
and the data from American IPF patients coming from Denver
(n = 488), Chicago (n= 95) and Pittsburgh (n = 246), previously
published [4,5].
Systemic sclerosis. The meta-analysis included data ob-
tained in the French and Italian populations from this study, and
data from American population of SSc patients from Northwest-
ern Scleroderma Program (n= 231) and controls from Denver
(n = 322), Chicago (n= 636) and Pittsburgh (n= 166) [4,5,8].
The combined data including the 4 populations of IPF, 3
populations of SSc and 5 populations of controls were analyzed by
calculation of homogeneity of ORs among the cohorts using the
Breslow-Day and Woolf Q methods, and by calculation of the
pooled ORs under a fixed-effects model (Mantel-Haenszel
metaanalysis) or random-effects model (DerSimonian-Laird) when
necessary and assessed by logistic regression analysis genetic effects
under 3 modes of inheritance: additive, dominant, and recessive.
Results
Idiopathic Pulmonary Fibrosis
The demographic and clinical characteristics of the subjects are
summarized in Table 1. The genotypic frequencies for rs35705950
were consistent with in Hardy–Weinberg equilibrium in the
controls populations.
Case-control analysis shows association of the rs35705950 SNP
with IPF (Table 2). The minor-allele frequency was 41.9% in the
Table 1. Characteristics of the French IPF patients.
French Population
N 142
Female 18%
Age, years 69.868.9
Smoker (active) 68% (4%)
Ethnic status
Caucasian
European 82%
North African 14%
Black 4%
Pulmonary Fonction
FVC (%) 76620
DLCO (%) 47619
Data are expressed as % or mean6 SD. IPF Idiopathic pulmonary fibrosis.
doi:10.1371/journal.pone.0070621.t001
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Table 2. Association between the MUC5B rs35705950 polymorphism and IPF, SSc and SSC-ILD in the European population.
TT (%) GT (%) GG (%) T (%) P OR [95% CI]
French populations
IPF n= 142 11.90 53.57 34.52 38.69 GT TT 4610229
9610229
6.4[4.5–9]
19[9–36]
SSc n= 981 1.22 17.53 81.24 9.99 G GG GT 0.36
0.61
0.42
0.91[0.76–1.11]
0.83[0.40–1.71]
0.92[0.74–1.14]
SSc-ILD+ n= 346 1.39 19.50 79.11 11.14 G GG GT 0.79
0.95
0.74
1.04[0.79–1.34]
0.97[0.36–2.61]
1.05[0.78–1.41]
SSc-ILD- n= 536 0.93 17.72 81.34 9.79 G GG GT 0.36
0.63
0.93
0.89[0.71–1.13]
0.63[0.24–1.70]
0.93[0.72–1.20]
Controls n= 1383 1.45 18.73 79.83 10.81
Italian populations
SSc n= 598 1.34 21.40 77.26 12.04 G GG GT 0.82
0.54
0.55
1.03[0.79–1.34]
0.75[0.29–1.95]
1.09[0.81–1.47]
SSc-ILD+ n= 207 1.45 24.15 74.40 13.53 G GG GT 0.35
0.79
0.21
1.17[0.84–1.65]
0.84[0.22–3.14]
1.28[0.87–1.82]
SSc-ILD-n= 384 1.30 19.79 78.91 9.79 G GGGT 0.72
0.54
0.95
0.9[0.71–1.13]
0.71[0.24–1.70]
0.99[0.72–1.20]
Controls n= 494 1.82 19.84 78.34 11.74
doi:10.1371/journal.pone.0070621.t002
Figure 1. Distribution of clinical characteristic according to theMUC5B genotype. (A) Distribution of age according to genotype. The centre
line of the box denotes the mean, the extremes of the box the interquartile range and the bars the highest and lowest values. (B) Distribution of the
gender according to the genotype. Percentage of men is represented in grey; percentage of women is represented in white with black dots. NS non
significant. (C) Distribution of the smoking status according to the genotype. Percentage of never smokers is represented in grey, percentage of past
smokers is represented in white, and percentage of active smokers is represented in black. (D) Distribution of the ethnic status according to the
genotype. Percentage of European is represented in white, percentage of North African is represented in grey, and percentage of black patients is
represented in dark. * P = 0.0008.
doi:10.1371/journal.pone.0070621.g001
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IPF cohort compared to 10.8% in controls (P = 2.9610244). Odds
ratios for IPF in subjects who were heterozygous and homozygous
for the minor allele of rs35705950 were 6.3 (95% confidence
interval, [CI], 4.6 to 8.7) and 21.7 (95% CI, 10.4 to 45.3)
respectively.
In the IPF cohort, the distribution of homozygous and
heterozygous patients was not different according to gender, age,
smoking habitus, pulmonary function test or presence of a cancer
at diagnosis, even in subgroup analysis according to gender
(Figure 1). The MUC5B rs35705950 IPF risk allele was not
detected in the French black individuals with IPF (P= 0.0008).
Systemic sclerosis
The demographic and clinical characteristics of the subjects are
summarized in Table 3.
Regarding the French population of SSc, no allelic association
was detected between the MUC5B rs35705950 SNP and the
overall disease: the minor allele was found in 10% of SSc
individuals compared to 10.8% in controls (P = 0.36). We failed to
detect any statistical difference of the genotypes distribution
between SSc patients with and without ILD and the controls in the
French population (Table 2). Similar allelic and genotypic
frequencies were observed in the Italian population, the lack of
association between SSc with or without ILD and MUC5B
rs35705950 being replicated (Table 2). In the SSc cohorts, the
distribution of homozygous and heterozygous patients was not
different according to gender.
Meta-analysis
The demographic and clinical characteristics of the subjects are
summarized in Table 4.
Remarkably, the genotypic frequencies were very similar in the
French and American populations of IPF and controls. The meta-
analysis of the 4 IPF populations evidenced a strong association
between MUC5B rs35705950 T allele and IPF: P = 56102105, OR
6.2 95% CI[5.3–7.3] (Figure 2).
The genotypic frequencies of the herein study were very similar
to that observed in the North American populations of SSc and
SSc-ILD. The meta-analysis of the 3 SSc populations confirmed
the absence of association between MUC5B rs35705950 T allele
and SSc whatever the presence of an ILD, OR 0.97 (95% CI, 0.84
to 1.12), P = 0.64, for the association with SSc, and OR 1.09 (95%
CI, 0.9 to 1.32), P = 0.38, for the association with SSc-ILD
(Figure 3).
Discussion
In this study, we confirm in European populations an
association between the MUC5B rs35705950 T allele and IPF
and a lack of association with SSc related ILD. Despite a relative
low number of IPF patients included, the meta-analysis provides a
definitive conclusion about this association in Caucasian popula-
tion. Interestingly, we observed that this polymorphism was absent
in the six black patients with IPF.
Our meta-analysis provides a more accurate evaluation of the
IPF risk associated with the T allele in Caucasian population.
Table 3. Characteristics of the SSc patients in the 2 investigated European populations.
French Population n=981 Italian Population n=598
Female (%) 83.6 86.1
Mean age, years 57.2612.8 53.6610.9
Mean disease duration, years 10.968.7 11.568.9
Limited cutaneous subtype (%) 64.5 69.9
Anti-Topo I positive patients (%) 27.3 29.9
ACA positive patients (%) 40.3 42.1
ILD on CT scan (%) 35.2% 34.6%
Anti-Topo I: anti-topoisomerase I antibodies; ACA: anti-centromere antibodies; ILD interstitial lung disease. Data are expressed as % or mean 6 SD. SSc systemic
sclerosis. ILD Interstitial lung disease.
doi:10.1371/journal.pone.0070621.t003
Table 4. Characteristics of the populations investigated for
meta-analysis.
IPF
Controls
for IPF SSc SSc-ILD+
Controls
for SSc
N 975 2353 1810 662 2045
Female (%) 26.8 55.5* 89.9 83.6 62.4*
Caucasian (%) 100 100 na na 100
Mean age, years 68.7 48.0* 54.5 56.5 45.2*
FVC (%) 66.9* na 85.5* 82.4* NA
DLCO (%) 45.9* na 65.1* 54.9* NA
*some data may be missing but data expressed represent always more than 2/3
of the populations. na not available.
doi:10.1371/journal.pone.0070621.t004
Figure 2. Meta-analysis of the MUC5B rs35705950 T allele risk
in the three American cohorts and the French cohort of
idiopathic pulmonary fibrosis (IPF). Forrest plots of the meta-
analysis of the association of the MUC5B rs35705950 T polymorphism
and IPF. Bars represent the 95% interval.
doi:10.1371/journal.pone.0070621.g002
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Remarkably the prevalence of the T allele risk in the cohorts of
controls, SSc, SSc-ILD or IPF was almost similar in every
population, including the English cohorts [9]. Indeed these cohorts
are large and probably representative of the entire Caucasian
population.
The Odd Ratio for IPF in heterozygotous carriers of the T allele
is 6, whereas almost 10% of the control population presents with
the T allele. The exact role of this polymorphism in IPF
pathophysiology remains to be determined. Seibold et al. suggested
that rs35705950 was functional [4]. Indeed, in unaffected subjects,
the presence of the T allele was associated with a 37 fold increased
expression of MUC5B gene in the lung. Furthermore, MUC5B
expression was increased 14-fold in the lung in IPF patients when
compared to controls. MUC5B is the dominant gel-forming mucin
in the normal distal airway epithelium. Plantier and colleagues
demonstrated by immunohistochemistry that, in contrast to
chronic obstructive pulmonary disease, MUC5B was the predom-
inant mucin detected in the abnormal mucus cells observed in the
honeycombing areas of the fibrotic lung in patients with IPF [13].
This result was confirmed by Seibold and coll. [14]. Interestingly a
trend was observed by Stock and colleagues between the MUC5B
variant and slower decline in forced vital capacity, whereas no
difference was evidenced in this cohort regarding age or severity at
diagnosis between carriers or non carriers of the T allele risk [9].
Some have suggested that a therapy targeting MUC5B transcrip-
tional activity should be evaluated in IPF [15]. The association
between increased expression of MUC5B and IPF suggest that
MUC5B may have a direct role in the pathogenesis of IPF.
MUC5B may interfere with the normal repair process of the
alveolar epithelium. For instance, MUC5B overexpression leads to
an aggressive behavior of breast cancer MCF7 cells with increased
proliferation and invasion in vitro, although the mechanisms
involved are unknown [16]. One may speculate whether MUC5B
overexpression stimulates a fibroproliferative response, or associ-
ates with abnormal mucosal defences to exogenous injury. Very
recently, the MUC5B rs35705950 T allele has been shown to be
associated with better survival among patients with IPF [17].
Further studies are clearly needed to better understand this
elective link between MUC5B overexpression and IPF and the
absence of link with other fibrotic lung diseases.
Our meta-analysis clearly suggests that the T allele is not
associated with an increase risk of SSc or ILD in SSc in the
Caucasian population. This is a very important result as it may
shed some light on specific lung fibrotic process in SSc. The
radiological and pathological pattern in IPF is UIP. In SSc,
different patterns have been described but the prominent pattern is
NSIP [2,18,19]. To date, the SSc-ILD pathogenesis remains
poorly understood. If the exact genetic contribution to SSc-ILD
remains unknown, a population-based study provided evidence for
the heritability of ILD in SSc, first-, third-, and fourth-degree
relatives of individuals with SSc having significantly elevated
relative risks for ILD [20]. In line with this, it has been previously
identified that some of the SSc risk variants, such as IRF5
rs20046640, STAT4 rs7574865 and NLRP1 rs8182352 suscepti-
bility alleles, contribute to a disease-specific phenotype, notably
SSc-ILD [11,21,22]. The lack of an association between the
MUC5B rs35705950 T allele and SSc related ILD suggest that this
polymorphism does not associate with lung fibrosis in general, but
might be specific for either IPF or UIP. Evaluating the prevalence
of MUC5B polymorphism in large cohorts of idiopathic or non-
idiopathic ILD may improve our understanding of the patho-
physiology of these diseases.
Our IPF population included only 6 black patients with IPF; the
MUC5B polymorphism was absent in all of them. There is paucity
of data regarding prevalence of IPF in black populations. In the 3
American cohorts of IPF evaluating the prevalence of MUC5B
polymorphism, all subjects were white [4,5]. Nathan and al.
reported a 13.8% prevalence of black in their IPF cohort from
Fairfax [23], whereas Swigris and al. recently reported twice less
IPF and a decreased risk of death from IPF in black descendents
[24]. Further studies including a re-sequencing of MUC5B in
other populations than Caucasian are required to better evaluate
the contribution of MUC5B in the genetic IPF background in
distinct populations. Distribution of T allele risk was not different
according to gender. However woman represent only 18% of the
cohort, that is less than the 28% of the Fairfax cohort [23].
Altogether, European data and meta-analysis confirm a strong
association between the MUC5B rs35705950 variant and IPF in
Caucasian population whereas this association was absent in SSc-
related ILD. Further studies are required to evaluate this genetic
susceptibility marker as a prognosis factor in IPF.
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Figure 3. Meta-analysis of the MUC5B rs35705950 T allele risk
in the two European (French and Italian) cohorts and the
American cohort of systemic sclerosis (SSc). Forrest plots of the
meta-analysis of the association of the MUC5B rs35705950 T polymor-
phism and (A) all SSc and (B) SSc with interstitial lung disease. Bars
represent the 95% interval.
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